# US 2012/0252092 A1 · Clostridium histolyticum recombinant collagenases and method for the manufacture thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252092 A1
- Document ID: US20120252092A1
- Status: Published application
- Kind: A1
- Application number: 13/515,203
- Filed: 2010-12-15
- Published: 2012-10-04
- Earliest claimed: 2009-12-15
- Assignees: ABIEL S.r.l.
- Inventors: Federico Bertuzzi; Angela Cuttitta; Giulio Ghersi; Salvatore Mazzola; Monica Salamone; Gregorio Seidita
- Web page: https://patentgrep.com/patent/US20120252092A1

## CPC

- C12N 9/52: derived from bacteria {or Archaea}
- C12N 9/6491: {Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)}
- C12Y 304/24003: Microbial collagenase (3.4.24.3)
- C07K 2319/24: containing a MBP (maltose binding protein)-tag
- C07K 2319/50: containing protease site
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to the production of recombinant collagenases, and in particular describes a method for the production of recombinant Clostridium histolyticum collagenases CoI characterized by a yield higher than approximately 140 mg/l of culture of said collagenases in soluble and biologically active form, collagenases produced by this method, compositions comprising these collagenases and the use thereof.

## Claims

### Claim 1

A method for production of recombinant C. histolyticum collagenase comprising:
a) designing a nucleotide optimized sequence for expression of said collagenase of C. histolyticum;
b) introducing, in an inducible expression vector, an oligonucleotide sequence coding for a fusion protein, wherein said oligonucleotide sequence consists in said optimized sequence fused to a nucleotide sequence coding for a soluble polypeptide and wherein said oligonucleotide sequence is operatively linked to an inducible promoter sequence, a transcription start sequence, and a termination sequence;
c) transforming a bacterial strain defective in expression of endogenous proteases with said expression vector;
d) culturing said transformed bacterial strain at a temperature in a range from 28° C. to 32° C.;
e) inducing expression of said fusion protein by adding a suitable inductor in said bacterial strain;
f) extracting the fusion protein obtained at point e); and
g) purifying said fusion protein;
wherein said method provides a yield higher than 140 mg/l of culture of said collagenase in soluble and enzymatically active form.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said temperature is about 30° C.

### Claim 3 (depends on 1)

The method according to claim 1 wherein said optimised sequence is fused to said soluble polypeptide coding sequence through a binding sequence coding for at least one cleavage site for a suitable proteolytic enzyme and further comprising:
h) obtaining said C. histolyticum collagenase by enzymatically cleaving said binding sequence.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said collagenase is a fusion protein MBP-C. histolyticum ColG and MBP-C. histolyticum ColH.

### Claim 5 (depends on 3)

The method according to claim 3, wherein said recombinant collagenases are the C. histolyticum ColG collagenase and the C. histolyticum ColH collagenase.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said nucleotide sequence is SEQ ID N: 1 sequence or SEQ ID NO: 3.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said expression vector is selected from the group consisting of the vector classes: pMAL, pRSET, pTAC, pFLAG, pET, and pT7.

### Claim 8 (depends on 7)

The method according to claim 7, wherein said expression vector of the pMAL class is vector pMAL-c2X and said expression vector of the pRSET class is vector pRSET-A.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said vector further comprises one or more control sequences operatively linked to said fusion protein selected from the group consisting of an enhancer sequence, a ribosome binding site, a sequence coding for a repressor, an operator sequence, a polyadenylation sequence, and a replication origin.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said “purification tag” is selected from the group consisting of: poly/hexahistidine tag, glutathione-S-transferase (GST), maltose binding protein (MBP), thioredoxin, protein A fragment of Staphylococcus aureus (ZZ), peptide with affinity for streptavidin (Strep-tag), and flag peptide.

### Claim 11 (depends on 1)

The method according to claim 1, wherein said bacterial strain is selected from the group consisting of lysogen Escherichia coli strains from D3 series, Escherichia coli strains with a Ion and/or ompT and/or dnaJ genotype, and BL21, BL21 AI, C600, CJ236, GC5, GM48, HB101, JM83, JM101, JM103, JM105, JM107, JM109, JM110, K802, LE392, MC1061, MM294, NM477, NM522, NM554, NM621, RR1, X1776, Rosetta(DE3)pLysS, DH5α, DH10B, ER2566, CAG597, CAG629, ER2508, UT5600, CAG626, PR1031, KS1000, ER2507, and TB1 Escherichia coli strains.

### Claim 12 (depends on 1)

The method according to claim 1, wherein said inductor is isopropyl β-D-1-thiogalactopyranoside (IPTG) for an expression vector of pMAL, pGEX, pTAC or pFLAG class or arabinose for an expression vector of pRSET, pET or pT7 class in the BL21-AI strain.

### Claim 13 (depends on 3)

A C. histolyticum recombinant collagenase obtainable by the method according to claim 3, characterised in that cells extracted with said collagenase maintain a differentiated phenotype.

### Claim 14 (depends on 13)

The C. histolyticum recombinant collagenase according to claim 13, wherein said recombinant collagenase is C. histolyticum ColG collagenase or C. histolyticum ColH collagenase.

### Claim 15

A C. histolyticum recombinant collagenase in the form of an MPB-Col fusion protein.

### Claim 16

A C. histolyticum recombinant collagenase wherein said collagenase is MBP-C. histolyticum ColG or MBP-C. histolyticum ColH.

### Claim 17 (depends on 1)

C. histolyticum recombinant collagenase in the form of MPB-Col fusion protein obtainable by the method according to claim 1.

### Claim 18 (depends on 13)

A composition comprising one or more C. histolyticum recombinant collagenases according to claim 13 and a suitable excipient.

### Claim 19 (depends on 13)

A kit for extraction of stem and/or somatic living cells from tissues comprising one or more aliquots of a C. histolyticum recombinant collagenase composition and/or of a composition thereof according to claim 13 and one or more aliquots of reagents for extraction of said cells.

### Claim 20 (depends on 18)

The kit according to claim 18, wherein said reagents suitable for the extraction comprise neutral proteases and/or thermolysin.

### Claim 21 (depends on 13)

A method of using C. histolyticum collagenase according to claim 13 or a composition comprising one or more C. histolyticum recombinant collagenases thereof, the method comprising extracting stem and/or somatic living cells from a tissue with said collagenase or said composition.

### Claim 22 (depends on 21)

The method according to claim 21, wherein said extraction results in isolation of living islets of Langherans from pancreas.

### Claim 23 (depends on 13)

C. histolyticum collagenase according to claim 13, wherein the number of living cells with normal phenotype extracted with C. histolyticum ColG is at least of about 7.4×105 cells/ml and the number of living cells with normal phenotype extracted with C. histolyticum ColH is at least of about 8.2×105 cells/ml in the in vitro extraction assay.
